Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 9, 2012, Pages 858-865

  Papay, P ^a   Primas, C ^a   Eser, A ^a   Novacek, G ^a   Winkler, S ^a   Frantal, S ^a   Angelberger, S ^a   Mikulits, A ^a   Dejaco, C ^a   Kazemi Shirazi, L ^a   Vogelsang, H ^a   Reinisch, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84878597071     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12037     Document Type: Article

References (45)

1. Keane J, Gershon S, Braun MS, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001; 345: 1098-104.
2. Marehbian J, Arrighi MH, Hass S, Tian H, Sandborn WJ, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-33.
3. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than soluble tumor necrosis factor receptor therapy. Arthritis Rheum 2009; 60: 1884-94.
4. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
5. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
6. Rutgeers P, Van Assche G, Vermiere S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006; 23: 451-63. (Pubitemid 43381999)
7. Data on file, Abbott, Analysis of Rheumatoid arthritis clinical trials 4/2006. Abbott, Chicago, IL, USA.
8. Ingram PR, Fisher DA, Wilder-Smith A. Review: latent tuberculosis infection in travelers: is there a role for Screening using interferon-gamma release assays? J Travel Med 2009; 16: 352-6.
9. Cobelens F, Van Deutekom H, Draayer-Jansen I, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356: 461-5. (Pubitemid 30496817)
10. Cobelens F, Van Deutekom H, Draayer-Jansen I, et al. Association of tuberculin sensitivity in Dutch adults with history of travel to areas with a high incidence tuberculosis. Clin Infect Dis 2001; 33: 300-4. (Pubitemid 32664831)
11. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel surveillance network. Clin Infect Dis 2006; 43: 1185-93. (Pubitemid 44632804)
12. Diel R, Golleti D, Ferrara G, et al. Interferon-y Release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
13. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. Quantiferon TB Gold Testing for tuberculosis screening in an inflammatory bowel disease cohort in United States. Inflamm Bowel Dis 2011; 17: 76-83.
14. Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-γ release assay in screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 84-90.
15. Schoepfer AM, Flogerzi B, Falleger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799-806.
16. Bélard R, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON Gold In-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011; 17: 2340-9.
17. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
18. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
19. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl. A): 5-36.
20. Oefferlbauer-Ernst A, Miehsler W, Eckmüller O, et al. Impact of interobserver disagreement on phenotype-genotype associations in Crohn's disease. Inflamm Bowel Dis 2007; 13: 156-63. (Pubitemid 46806224)
21. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
22. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34: 365-70. (Pubitemid 34062238)
23. American Thoracic Society. Targeted tuberculin testing. And treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-47.
24. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-6. (Pubitemid 35417778)
25. Van Zyl-Smit RN, Zwerling A, Dheda K, et al. Within-Subject variability of Interferon-g Assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009; 4: e8517.
26. Schablon A, Harling M, Diel R, Ringshausen FC, Torres Costa J, Nienhaus A. Serial testing with interferon-y release assay in German healthcare workers. GMS Krankenhhyg Interdiszip 2010; 5: Doc05.
27. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-6.
28. Bermejo F, Algaba A, Chapparo M, et al. How frequent are conversions of tuberculosis screening tests among inflammatory bowel disease patients under anti-TNF treatment? J Crohns Colitis 2012; 6(Suppl. 1): S76.
29. Lee SW, Lee CT, Yim JJ. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 2010; 10: 300.
30. Adetifa IM, Ota MO, Walther B, et al. Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. PLoS ONE 2010; 5: e12502.
31. Chee CB, Khin Mar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010; 36: 355-61.
32. Wilkinson KA, Kon OM, Newton SM, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigen. J Infect Dis 2006; 193: 354-9. (Pubitemid 43122334)
33. Pai M, Joshi R, Dogra S, et al. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 2006; 1: 7.
34. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Mørkve O. Diagnosis and follow-up of treatment of latent tuberculosis: the utility of Quantiferon TB Gold in tube assay in outpatients from tuberculosis low-endemic country. BMC Infect Dis 2010; 10: 57.
35. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disase: a systematic revie and Meta-analysis. Inflamm Bowel Dis 2012; doi: 10.1002/ibd.22901 [Epub ahead of print].
36. Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-c release assay in screening for latent TB in inflammatory bowel diseses. Eur J Clin Invest 2011; 41: 1071-6.
37. Helwig U, Müller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the results of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis 2012; 6: 419-24.
38. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole-blood IFN-c assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-70. (Pubitemid 351717577)
39. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by whole-blood interferon-c release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 54-62.
40. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
41. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
42. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
43. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
44. Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007; 25: 1373-88. (Pubitemid 46860226)
45. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 19-30. (Pubitemid 350212629)